Events & Presentations

Date	Event Details	Remind Me
May 17, 2022 4:35 PM EDT	2022 RBC Capital Markets Global Healthcare Conference View Additional Information Type: Fireside chat presentation Presenter: Christopher Anzalone, President and CEO, Arrowhead Pharmaceuticals Listen to webcast
May 25, 2022 12:15 PM EDT	UBS Global Healthcare Conference 2022 View Additional Information Type: Fireside chat presentation Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals	Add to Outlook Add to Google Calendar
May 26, 2022 10:00 AM EDT	Pulmonary R&D Day Listen to webcast Location: New York	Add to Outlook Add to Google Calendar

Date	Event Details
May 13 - May 18, 2022	2022 American Thoracic Society (ATS) International Conference View Additional Information Title: Silencing RAGE Expression with a Lung-Targeted RNAi Trigger Delivery Platform Suppresses Pulmonary Allergic Inflammation Presenter: David Kasahara, Senior Scientist III, Biology, Arrowhead Pharmaceuticals Title: Silencing Muc5ac Expression with a Lung-Targeted RNAi Trigger Prevents Allergen-Induced Mucoobstruction and Airway Hyperresponsiveness Presenter: David Kasahara, Senior Scientist III, Biology, Arrowhead Pharmaceuticals
May 12, 2022 1:40 PM EDT	BofA Securities 2022 Healthcare Conference Listen to webcast View Additional Information Type: Fireside chat presentation Presenter: Christopher Anzalone, President and CEO, Arrowhead Pharmaceuticals
May 10, 2022 4:30 PM EDT	Arrowhead Pharmaceuticals 2022 Second Quarter Results Listen to webcast Supporting Materials: Prepared Remarks 260.5 KB
May 9 - May 12, 2022	TIDES USA 2022: Oligonucleotide and Peptide Therapeutics Supporting Materials: View Presentation 3.5 MB View Additional Information Title: Arrowhead’s Approach to Oligonucleotide Scale-Up Manufacturing Presenter: Michael Lawler, Director, Chemistry, Arrowhead Pharmaceuticals
Apr 25 - Apr 27, 2022	DIA/FDA's Oligonucleotide-based Therapeutics Conference (Oligo22) Supporting Materials: DIA FDA 2022 ARO-HIF2 2.2 MB View Additional Information Title: Short Interfering RNA JNJ-3989 Combination Therapy Presenter: Michael Biermer, Senior Director, Clinical Development, Janssen Pharmaceuticals Title: ARO-HIF2 Evaluated in Clear Cell Renal Cell Carcinoma Ph1b Clinical Trial Presenter: James Hamilton, Senior Vice President, Discovery and Translational Medicine, Arrowhead Pharmaceuticals
Apr 8 - Apr 13, 2022	American Association for Cancer Research Annual Meeting 2022 (AACR) Supporting Materials: AACR 2022 ARO-HIF2 Poster 1.6 MB View Additional Information Title: Targeting HIF2a with siRNA: From preclinical models to the clinic Authors: Yuanqing Ma, et al.
Mar 30 - Apr 3, 2022	31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) Supporting Materials: APASL 2022 JNJ-3989 in Healthy Chinese 2.5 MB APASL 2022 JNJ-3989 in Hepatic Impaired 176.6 KB APASL 2022 JNJ-3989 927.4 KB View Additional Information Title: Pharmacokinetics and Safety of JNJ-73763989, an RNA Interference Therapy for Hepatitis B Virus, in Moderately Hepatically Impaired Participants Authors: Thomas N. Kakuda, et al. Title: Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants Authors: Haiyan Li, et al. Title: Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Authors: Edward Gane, et al.
Feb 17 - Feb 19, 2022	2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Supporting Materials: Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001) 1.5 MB View Additional Information San Francisco, CA and online Presentation Details: Title: Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001) Authors: James Brugarolas, et al. Session: Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers Abstract Number: 339 Poster Number: F9
Feb 2, 2022 4:30 PM EST	Arrowhead Pharmaceuticals 2022 First Quarter Results Listen to webcast Supporting Materials: Prepared Remarks 206.2 KB
Dec 3, 2021	18th Global Cardiovascular Clinical Trialists Forum Supporting Materials: View Presentation 1.1 MB View Additional Information James Hamilton, MD, MBA, Arrowhead’s senior vice president of discovery & translational medicine, will participate in a panel discussion titled, “Developments in Hypertriglyceridemia Trials”